Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) have been given a consensus rating of “Moderate Buy” by the fifteen brokerages that are currently covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation and thirteen have assigned a buy recommendation to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $47.50.
A number of research firms have weighed in on BBIO. HC Wainwright reiterated a “buy” rating and issued a $43.00 price target on shares of BridgeBio Pharma in a research report on Monday, September 30th. Piper Sandler began coverage on shares of BridgeBio Pharma in a research report on Wednesday, September 4th. They issued an “overweight” rating and a $46.00 price target for the company. Evercore ISI dropped their target price on shares of BridgeBio Pharma from $50.00 to $45.00 and set an “outperform” rating for the company in a research report on Wednesday, August 7th. Scotiabank began coverage on shares of BridgeBio Pharma in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $44.00 target price for the company. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $70.00 target price on shares of BridgeBio Pharma in a research report on Monday, September 16th.
View Our Latest Stock Analysis on BridgeBio Pharma
Insider Activity at BridgeBio Pharma
Institutional Investors Weigh In On BridgeBio Pharma
Several hedge funds and other institutional investors have recently made changes to their positions in BBIO. Bfsg LLC increased its stake in BridgeBio Pharma by 175.6% in the 2nd quarter. Bfsg LLC now owns 1,240 shares of the company’s stock worth $31,000 after buying an additional 790 shares during the period. Headlands Technologies LLC purchased a new position in BridgeBio Pharma in the 2nd quarter worth about $48,000. CWM LLC increased its stake in BridgeBio Pharma by 132.9% in the 3rd quarter. CWM LLC now owns 3,442 shares of the company’s stock worth $88,000 after buying an additional 1,964 shares during the period. EntryPoint Capital LLC purchased a new position in BridgeBio Pharma in the 1st quarter worth about $117,000. Finally, Amalgamated Bank grew its holdings in BridgeBio Pharma by 24.7% during the 2nd quarter. Amalgamated Bank now owns 4,863 shares of the company’s stock worth $123,000 after acquiring an additional 962 shares in the last quarter. Hedge funds and other institutional investors own 99.85% of the company’s stock.
BridgeBio Pharma Trading Down 0.9 %
Shares of BBIO stock opened at $24.94 on Wednesday. BridgeBio Pharma has a 12 month low of $21.62 and a 12 month high of $44.32. The stock has a market cap of $4.67 billion, a P/E ratio of -7.75 and a beta of 1.08. The company has a 50 day simple moving average of $26.12 and a two-hundred day simple moving average of $26.56.
BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) last announced its earnings results on Thursday, August 1st. The company reported ($0.39) EPS for the quarter, beating analysts’ consensus estimates of ($1.00) by $0.61. The business had revenue of $2.17 million for the quarter, compared to analysts’ expectations of $3.96 million. The firm’s quarterly revenue was up 32.1% on a year-over-year basis. During the same period in the prior year, the company posted ($0.98) earnings per share. As a group, equities analysts forecast that BridgeBio Pharma will post -2.56 earnings per share for the current year.
BridgeBio Pharma Company Profile
BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.
Recommended Stories
- Five stocks we like better than BridgeBio Pharma
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- How Verizon Could Offer Stress-Free Double-Digit Returns in 2025
- Which Wall Street Analysts are the Most Accurate?
- Can Roche Challenge Lilly and Novo in the Weight Loss Market?
- Investing in the High PE Growth Stocks
- Roblox Stock: Key Metrics Surge, Is This the Perfect Entry?
Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.